Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company markets three approved medicines: Livmarli (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, Cholbam (cholic acid) for bile acid synthesis disorders, and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. Mirum commercializes these products in the United States, Canada, and parts of Europe through a specialized commercial team and license agreements with rare disease partners. The company’s pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis D virus infection, and MRM-3379 for fragile X syndrome. Mirum was founded in 2018 and completed the acquisition of Bluejay Therapeutics in January 2026 to expand its portfolio.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage mirumpharma.com
Sector Healthcare IR page ir.mirumpharma.com/overview/default.aspx
Tags
rare diseases, hepatology, bile acid disorders, monoclonal antibodies, hepatitis d, fragile x syndrome, orphan drugs, clinical-stage pipeline, Livmarli, maralixibat, Cholbam, cholic acid, Ctexli, chenodiol, volixibat, brelovitug, BJT-778, MRM-3379, Bluejay Therapeutics, Travere Therapeutics
Press page —

Metrics

Valuation  
Market cap $ 6.018B
Market cap (USD) $ 6.018B
P/E -5.97
PEG —
P/BV -111.05
P/S 8.97
P/OCF -22.18
P/FCF -21.97
Dividend yield —
Turnover / mcap —
Returns  
ROE -8.6%
ROI -3.7%
ROIC -2.7%
Profit margin -4.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 98.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 108
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 521.312M 336.888M 186.374M 77.062M 19.138M — —
Net profit -23.363M -87.942M -163.415M -135.665M -83.988M -103.27M -52.553M
Free cash flow 54.873M 9.332M -71.053M -120.414M -132.782M -89.3M -39.643M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 78.99 41.35 29.52 19.5 15.95 17.46 24.52
Price performance 12m 0.91 0.4 0.51 0.22 -0.09 -0.29 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 0.00 3.27M 24M 68M 78.3M 123M
↳ YoY growth +634.4% +183.3% +15.2% +57.5%
Lease liabilities (USD) — 3.65M 3.26M 2.61M 2.19M 1.72M 9.68M 9.66M
Cash and deposits (USD) 52M 12M 142M 31.3M 28M 286M 223M 297M
Intangible assets (USD) — — 0.00 18.7M 59M 253M 250M 261M
Right-of-use assets (USD) — 2.36M 1.95M 1.57M 1.43M 1.28M 8.68M 8.74M
Cash flow detail
Operating cash flow (USD) — -39.4M -89.1M -133M -120M -70.9M 10.3M 55.8M
Purchases of property, plant and equipment (USD) — -281,000 -225,000 -24,000 -278,000 -109,000 -993,000 -954,000
Purchases of intangible assets (USD) — — — -19M 0.00 -20M -20M 0.00
Change in receivables (cash effect) (USD) — — — 0.00 -20.7M -44M -11.4M -48.1M
Change in inventories (cash effect) (USD) — — 0.00 495,000 -3.45M -4.39M -3.17M -8.45M
Interest paid (cash effect) (USD) — — — 0.00 0.00 -6.82M -12.7M -12.7M
Income taxes paid (cash effect) (USD) — -21,000 -11,000 0.00 0.00 -125,000 -1M -2.16M
Share-based compensation (USD) — 6.07M 12.6M 23.1M 27M 35M 48.4M 71.4M
Operating cash flow before change in receivables (USD) — — — -133M -99.4M -27M 21.8M 104M
Free cash flow (OCF - PPE - intangibles) (USD) — -39.6M -89.3M -133M -120M -91.1M -10.7M 54.9M
Income detail
Research and development expense (USD) — 43M 81.6M 131M 107M 103M 141M 186M
↳ 5y CAGR +26.7% +17.9%
Total comprehensive income (USD) — -52.4M -103M -84.1M -136M -162M -90M -22.6M
Comprehensive income to owners (USD) — -52.4M -103M -84.1M -136M -162M -90M -22.6M
Provision for credit losses (USD) — — — 0.00 0.00 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Aug 28, 2019 Mar 9, 2021 Mar 9, 2022 Mar 15, 2024 Mar 15, 2024 Mar 15, 2024 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Mirum Pharmaceuticals, Inc. — Other Events Bull 7 Bear 0 Clinical/regulatory

Announcement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases (“AASLD”) On November 10, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen, for the treatment of chronic hepatitis delta virus (“HDV”). AZURE-4 is the second of two Phase 3 studies that will form the basis of the Company’s U.S. registration package for brelovitug. The Company also highlighted brelovitug data presented at the AASLD’s The Liver Meeting®. Across three presentations, the data demonstrated deepening viral suppression, increased rates of alanine aminotransferase (“ALT”) normalization, and improvements in liver stiffness with longer brelovitug treatment, including in patients with advanced cirrhosis.

–Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million

–Received U.S. FDA approval of and launched ATEBRIOZ® for FOP

–Announced three positive readouts setting up planned regulatory submissions for LIVMARLI®, ATEBRIOZ and brelovitug

–Received U.S. FDA Orphan Drug Designation for brelovitug in HDV

–Conference call to provide business updates today, November 3 at 1:30 p.m. PT / 4:30 p.m. ET

FOSTER CITY, Calif. – November 3, 2026 – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update.

“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio,” said Chris Peetz, Chief Executive Officer of Mirum.

October 27, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report third quarter 2026 financial results on November 3, 2026. Mirum will also host a conference call to discuss the third quarter 2026 financial results and recent corporate progress.

**Conference call details:
**Tuesday, November 3, 2026
4:30 p.m. ET / 1:30 p.m. PT

**Dial-In:
**US/Toll-Free: +1 833 461 5787
International: +1 585 542 9983
Access Code: 414267773

You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), ATEBRIOZ™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM® (cholic acid) for bile-acid synthesis disorders and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook , LinkedIn , Instagram and X .

Investor Contact:
Andrew McKibben
[email protected]

Media Contact:
Meredith Kiernan
[email protected]

Source: Mirum Pharmaceuticals, Inc.

View All News

Investor Contacts

Andrew McKibben

​ 650-667-4085

​ [email protected]

Media Contact

Meredith Kiernan

​ [email protected]

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe


        instagram  linkedin  twitter  facebookInstall Free Assistive Technology

Mirum Pharma, Logo

© 2026 Mirum Pharmaceuticals, Inc. - All rights reserved

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Prompts

Mirum Pharmaceuticals, Inc. (ticker MIRM), listed in United States.

ETFs Holding Mirum Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 4.32% 55,641 $ 5.456M Aug 31, 2026
ILDR 1.03% 35,680 $ 3.268M Nov 16, 2026
BRES 0.88% 58,135 $ 5.35M Nov 18, 2026
FSCC 0.85% 31,599 $ 3.098M Aug 31, 2026
SCDS 0.46% 453 $ 41.653K Nov 17, 2026
FMED 0.42% 2,191 $ 214.828K Aug 31, 2026
RUSC 0.40% 2,682 $ 313.982K Jun 30, 2026
ESSC 0.39% 1,309 $ 138.689K Jul 31, 2026
EHLS 0.38% 2,261 $ 207.062K Nov 17, 2026
FSEG 0.38% 185 $ 21.658K Jun 30, 2026
PSC 0.30% 60,377 $ 7.068M Jun 30, 2026
AFSM 0.26% 4,117 $ 377.035K Nov 16, 2026
FTKI 0.24% 669 $ 61.267K Nov 16, 2026
TMSL 0.22% 50,744 $ 5.941M Jun 30, 2026
FESM 0.19% 94,246 $ 11.033M Jun 30, 2026
RESM 0.19% 58 $ 6,790.06 Jun 30, 2026
FFF 0.10% 73 $ 6,240.04 Sep 30, 2026
VFMO 0.09% 18,291 $ 1.793M Aug 31, 2026
AVIE 0.05% 92 $ 8,425.36 Nov 16, 2026
MSSM 0.02% 1,499 $ 146.977K Aug 31, 2026
AVUQ 0.00% 215 $ 19.69K Nov 16, 2026
NTRL short 0.00% -692 $ 0.00 Nov 16, 2026